Skip to content

Study · Randomized controlled trial · n = 6 · 1996

9 results

The effect of repeated administration of hexarelin, a growth hormone releasing peptide, and growth hormone releasing hormone on growth hormone responsivity.

Massoud AF, Hindmarsh PC, Matthews DR, Brook CG

Clinical endocrinology1 May 1996Cited by 5 (Europe PMC)

PMID8762732 (opens in a new tab)DOI10.1046/j.1365-2265.1996.722543.x (opens in a new tab)PepBankPUB-08762732
Publisher pagePubMedAsk about this study
Jump to 9 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study9

3 results from studies that gave the peptide. 3 results from people.

  1. 01HumanRandomized controlled trialActivity measurement

    In healthy adult males, the peak GH secretion rate after the first hexarelin bolus was greater than after the first GHRH-(1-29)-NH2 bolus (P < 0.001).

    In plain wordsIn healthy men, a first dose of hexarelin released more growth hormone than a first dose of GHRH.

    Peptide
    Hexarelin
    Outcome
    IncreasePeak GH secretion rate after first bolus, hexarelin vs GHRH
    Study

    n = 6

    Comparator
    GHRH-(1-29)-NH2
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    1 microgram/kg · intravenous · two boluses 60 or 120 minutes apartAs given in this study (human).

    Source sentences

    Summary
    The peak GH secretion rate following the first intravenous bolus of hexarelin was greater than that following the first bolus of GHRH-(1-29)-NH2 (P < 0.001)
    2 context sentences
    Summary · context
    Single boluses of hexarelin (1 microgram/kg), GHRH-(1-29)-NH2 (1 microgram/kg) or hexarelin with GHRH-(1-29)-NH2 were administered intravenously.
    Summary · context
    Six healthy adult males (25.4-34.1 years) were studied.
  2. 02HumanRandomized controlled trialActivity measurement

    In healthy adult males, a second hexarelin bolus caused significant further GH secretion compared with saline (P = 0.02).

    In plain wordsIn healthy men, a second dose of hexarelin still released growth hormone, more than saline did.

    Peptide
    Hexarelin
    Outcome
    IncreaseGH secretion after a second hexarelin bolus vs saline
    Study

    n = 6

    Comparator
    Saline
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    1 microgram/kg · intravenous · two boluses 60 or 120 minutes apartAs given in this study (human).

    Source sentences

    Summary
    Compared to saline, the administration of a second bolus of hexarelin, GHRH-(1-29)-NH2 or both resulted in significant further GH secretion (P = 0.02, P = 0.002, P = 0.03, respectively)
    2 context sentences
    Summary · context
    Single boluses of hexarelin (1 microgram/kg), GHRH-(1-29)-NH2 (1 microgram/kg) or hexarelin with GHRH-(1-29)-NH2 were administered intravenously.
    Summary · context
    Six healthy adult males (25.4-34.1 years) were studied.
  3. 03HumanRandomized controlled trialActivity measurement

    In healthy adult males, a second hexarelin bolus given 120 minutes after the first produced lower peak GH secretion rates (P = 0.03).

    In plain wordsIn healthy men, a second dose of hexarelin given two hours after the first released less growth hormone than the first.

    Peptide
    Hexarelin
    Outcome
    DecreasePeak GH secretion rate after second hexarelin bolus at 120 minutes
    Study

    n = 6

    Comparator
    First hexarelin bolus
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    1 microgram/kg · intravenous · second bolus 120 minutes after the firstAs given in this study (human).

    Source sentences

    Summary
    The administration of a second bolus of hexarelin or hexarelin with GHRH-(1-29)-NH2 120 minutes after the first bolus resulted in lower peak GH secretion rates (P = 0.03).
    2 context sentences
    Summary · context
    Single boluses of hexarelin (1 microgram/kg), GHRH-(1-29)-NH2 (1 microgram/kg) or hexarelin with GHRH-(1-29)-NH2 were administered intravenously.
    Summary · context
    Six healthy adult males (25.4-34.1 years) were studied.

Studies that did not test the peptide alone6

In this study, Hexarelin was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Hexarelin.

  1. 04HumanNot a test of Hexarelin aloneRandomized controlled trialActivity measurement

    In healthy adult males, the peak GH secretion rate was greatest after hexarelin given together with GHRH-(1-29)-NH2 (P < 0.001).

    In plain wordsIn healthy men, hexarelin given together with GHRH released the most growth hormone of the three treatments.

    Peptide
    Hexarelin
    Outcome
    IncreasePeak GH secretion rate after first bolus, hexarelin with GHRH
    Study

    n = 6

    Comparator
    Hexarelin alone and GHRH alone
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones

    Source sentences

    Summary
    and was greatest following the administration of hexarelin with GHRH-(1-29)-NH2 (P < 0.001)
    2 context sentences
    Summary · context
    Single boluses of hexarelin (1 microgram/kg), GHRH-(1-29)-NH2 (1 microgram/kg) or hexarelin with GHRH-(1-29)-NH2 were administered intravenously.
    Summary · context
    Six healthy adult males (25.4-34.1 years) were studied.

    In this study, Hexarelin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Hexarelin.

  2. 05HumanNot a test of Hexarelin aloneRandomized controlled trialActivity measurement

    In healthy adult males, hexarelin with GHRH-(1-29)-NH2 gave peak GH secretion rates greater than the arithmetic sum of the isolated administrations (P = 0.001), showing synergism.

    In plain wordsIn healthy men, hexarelin and GHRH given together released more growth hormone than the two given separately added up.

    Peptide
    Hexarelin
    Outcome
    IncreaseSynergy of hexarelin with GHRH on peak GH secretion
    Study

    n = 6

    Comparator
    Arithmetic sum of the isolated administrations
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones

    Source sentences

    Summary
    The coadministration of the two secretagogues resulted in peak GH secretion rates significantly greater than the arithmetic sum of those following their isolated administration (P = 0.001), demonstrating synergism.
    2 context sentences
    Summary · context
    Single boluses of hexarelin (1 microgram/kg), GHRH-(1-29)-NH2 (1 microgram/kg) or hexarelin with GHRH-(1-29)-NH2 were administered intravenously.
    Summary · context
    Six healthy adult males (25.4-34.1 years) were studied.

    In this study, Hexarelin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Hexarelin.

  3. 06HumanNot a test of Hexarelin aloneRandomized controlled trialActivity measurement

    In healthy adult males, a second bolus of hexarelin with GHRH-(1-29)-NH2 caused significant further GH secretion compared with saline (P = 0.03).

    In plain wordsIn healthy men, a second dose of hexarelin with GHRH still released growth hormone, more than saline did.

    Peptide
    Hexarelin
    Outcome
    IncreaseGH secretion after a second bolus of hexarelin with GHRH vs saline
    Study

    n = 6

    Comparator
    Saline
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones

    Source sentences

    Summary
    Compared to saline, the administration of a second bolus of hexarelin, GHRH-(1-29)-NH2 or both resulted in significant further GH secretion (P = 0.02, P = 0.002, P = 0.03, respectively).
    2 context sentences
    Summary · context
    Single boluses of hexarelin (1 microgram/kg), GHRH-(1-29)-NH2 (1 microgram/kg) or hexarelin with GHRH-(1-29)-NH2 were administered intravenously.
    Summary · context
    Six healthy adult males (25.4-34.1 years) were studied.

    In this study, Hexarelin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Hexarelin.

  4. 07HumanNot a test of Hexarelin aloneRandomized controlled trialActivity measurement

    In healthy adult males, a second bolus of hexarelin with GHRH-(1-29)-NH2 given 120 minutes after the first produced lower peak GH secretion rates (P = 0.03).

    In plain wordsIn healthy men, a second dose of hexarelin with GHRH given two hours after the first released less growth hormone than the first.

    Peptide
    Hexarelin
    Outcome
    DecreasePeak GH secretion rate after second bolus of hexarelin with GHRH at 120 minutes
    Study

    n = 6

    Comparator
    First bolus of hexarelin with GHRH
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones

    Source sentences

    Summary
    The administration of a second bolus of hexarelin or hexarelin with GHRH-(1-29)-NH2 120 minutes after the first bolus resulted in lower peak GH secretion rates (P = 0.03).
    2 context sentences
    Summary · context
    Single boluses of hexarelin (1 microgram/kg), GHRH-(1-29)-NH2 (1 microgram/kg) or hexarelin with GHRH-(1-29)-NH2 were administered intravenously.
    Summary · context
    Six healthy adult males (25.4-34.1 years) were studied.

    In this study, Hexarelin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Hexarelin.

  5. 08HumanNot a test of Hexarelin aloneRandomized controlled trialActivity measurement

    In healthy adult males, the reductions in peak GH secretion rates after second boluses of hexarelin or hexarelin with GHRH-(1-29)-NH2 given 60 minutes after the first were not statistically significant.

    In plain wordsIn healthy men, a second dose of hexarelin, alone or with GHRH, given one hour after the first did not release significantly less growth hormone.

    Peptide
    Hexarelin
    Outcome
    No significant changeReduction in peak GH secretion after 60-minute boluses
    Study

    n = 6

    Comparator
    First bolus
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones

    Source sentences

    Summary
    The reductions in peak GH secretion rates following the 60-minute boluses were not statistically significant.
    2 context sentences
    Summary · context
    Single boluses of hexarelin (1 microgram/kg), GHRH-(1-29)-NH2 (1 microgram/kg) or hexarelin with GHRH-(1-29)-NH2 were administered intravenously.
    Summary · context
    Six healthy adult males (25.4-34.1 years) were studied.

    In this study, Hexarelin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Hexarelin.

  6. 09HumanNot a test of Hexarelin aloneRandomized controlled trialActivity measurement

    In healthy adult males, after second boluses the peak GH secretion rates with hexarelin and GHRH-(1-29)-NH2 together were not significantly different from the arithmetic sum of the separate second boluses, indicating loss of synergism.

    In plain wordsIn healthy men, the added effect of hexarelin and GHRH together was lost when the doses were repeated.

    Peptide
    Hexarelin
    Outcome
    No significant changeSynergy of hexarelin with GHRH on repeated administration
    Study

    n = 6

    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones

    Source sentences

    Summary
    Irrespective of the interval between the boluses of hexarelin with GHRH-(1-29)-NH2, the peak GH secretion rates following the second boluses were not significantly different from the arithmetic sum of those following the administration of the second boluses of hexarelin or GHRH-(1-29)-NH2, indicatin…
    2 context sentences
    Summary · context
    Single boluses of hexarelin (1 microgram/kg), GHRH-(1-29)-NH2 (1 microgram/kg) or hexarelin with GHRH-(1-29)-NH2 were administered intravenously.
    Summary · context
    Six healthy adult males (25.4-34.1 years) were studied.

    In this study, Hexarelin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Hexarelin.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    13 Oct 2026, 21:44 UTC

    Study results updated

  2. Version 2

    13 Oct 2026, 16:31 UTC

    Study data updated · source update from Europe PMC

  3. Version 1

    9 Oct 2026, 03:13 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.